FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Delayed Deutsche Boerse AG 15:35:59 17/06/2024 BST | ||
| 0.54 EUR | +8.00% |
|
| Current month | -20.63% | ||
| 1 month | -16.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 17/06/24 | 0.54 | +8.00% |
| 14/06/24 | 0.5 | -9.09% |
| 13/06/24 | 0.55 | +1.85% |
| 12/06/24 | 0.54 | -1.82% |
| 11/06/24 | 0.55 | +14.58% |
Delayed Quote Deutsche Boerse AG
Last update June 17, 2024 at 03:35 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SQ628R |
| ISIN | DE000SQ628R3 |
| Date issued | 09/01/2023 |
| Strike | 11,713 p |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.71 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 27.39 € |
|---|---|
| Lowest since issue | 0.45 € |
| Spread | 0.01 € |
| Spread % | 1.82% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.6
USD
Average target price
174.4
USD
Spread / Average Target
+9.95%
- Stock Market
- Certificates
- Certificat